[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuromyelitis-optica-spectrum-disorders-nmosd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuromyelitis-optica-spectrum-disorders-nmosd":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,86,116,143,169,195],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054309","phase-4-crisugabalin-in-nmosd-neuropathic-pain-a-randomized-double-blind-placebo-controlled-exploratory-trial-100054309",false,"NCT07699770","Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial","Efficacy and Safety of Crisugabalin in Treating Neuropathic Pain Related to Neuromyelitis Optica Spectrum Disorders: a Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled, Exploratory Trial","TERMINATOR","\\*\\*Inclusion Criteria:\\*\\*\n\nSubjects who meet all of the following criteria will be enrolled in this study:\n\n1. Able to understand and voluntarily sign the written informed consent form;\n2. Male or female aged between 18 years (inclusive) and 75 years;\n3. Diagnosed with aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) according to the International Panel for NMO Diagnosis (IPND, 2015) criteria;\n4. Patients with comorbid neuropathic pain, DN4 ≥ 4; no change in medication dosage within the past month;\n5. Numeric Rating Scale (NRS) for pain score ≥ 4 at screening;\n6. First-time use of Crisugabalin Capsules.\n\n\\*\\*Exclusion Criteria:\\*\\*\n\nSubjects who meet any of the following criteria will not be enrolled in this study:\n\n1. Presence of peripheral neuropathy or pain unrelated to NMOSD that, in the investigator's judgment, may confound the assessment;\n2. Known history of allergy to the investigational drug components, or to other drugs with similar chemical structures, or to any excipients;\n3. Prior use of pregabalin ≥ 300 mg\u002Fday, gabapentin ≥ 1200 mg\u002Fday, or mirogabalin ≥ 30 mg\u002Fday with lack of clinical efficacy as judged by the investigator;\n4. Severe liver or kidney function abnormalities, meeting any of the following clinical laboratory findings:\n\n1\\) Liver function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3 × upper limit of normal (ULN); 2) Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m² (calculated using the simplified MDRD formula); 5. Women who are pregnant, planning to become pregnant during the study period, or currently breastfeeding; subjects who are unwilling to use reliable contraceptive measures (including condoms, spermicides, intrauterine devices, etc.) from the time of signing the ICF until 28 days after the last dose of the investigational drug; 6. Current use of IL-6 receptor blockers (e.g., tocilizumab, satralizumab); 7. History of suicidal behavior or suicidal ideation; 8. Participation in any other clinical study within 30 days prior to screening; 9. The investigator determines that there are other situations in which participation in the study is inappropriate.","ALL","18 Years","75 Years",{"count":21,"type":22},110,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This study is a multicenter, prospective, randomized, double-blind, placebo-controlled exploratory investigation conducted in China.",[28,29],"Neuromyelitis Optica Spectrum Disorders (NMOSD)","Neuropathic Pain",[31,32,33,34],"neuromyelitis optica spectrum disorders","Neuropathic pain","Crisugabalin","NMOSD","NOT_YET_RECRUITING","2026-07-09",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":22},"2026-06-15",{"date":43,"type":22},"2027-12-31",{"name":45,"class":46},"Tang-Du Hospital","OTHER",10,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100641464","cohort-study-on-neuroimmune-diseases-in-the-reproductive-age-100641464","NCT07653984","Cohort Study on Neuroimmune Diseases in the Reproductive Age","RANID","Inclusion Criteria:\n\n* Patient Group: A total of fifty participants are expected to be enrolled.\n\n  1. Women aged 20-55 years with childbearing potential.\n  2. Voluntary informed consent.\n  3. Availability of complete personal information.\n  4. A confirmed diagnosis of neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), autoimmune encephalitis, myasthenia gravis, Guillain-Barré syndrome, or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).\n\nHealthy Control Group: A total of fifty healthy women are expected to be included.\n\n1. Age- and sex-matched women of childbearing age with plans for pregnancy\n2. Voluntary informed consent.\n3. Availability of complete personal information.\n\nExclusion Criteria:\n\n* Patient Group:\n\n  1. Patients with an undetermined or unconfirmed diagnosis.\n  2. Incomplete personal information that cannot be obtained through follow-up.\n  3. Participants who voluntarily withdrew from the study and revoked informed consent.\n\nHealthy Control Group:\n\n1. Individuals diagnosed with neuroimmune-related disorders.\n2. Incomplete personal information that cannot be obtained through follow-up.\n3. Participants who voluntarily withdrew from the study and revoked informed consent.",true,"FEMALE","20 Years","55 Years",{"count":60,"type":22},100,"OBSERVATIONAL","Neuroimmune diseases are more prevalent among women of reproductive age. Studies have shown that neuroimmune diseases may impact fertility. Therefore, effective management of neuroimmune diseases during pregnancy is particularly important. This study included a follow-up period of up to five years in patients with pregnancy-associated neuroimmune disorders. Data collected included relapse frequency, symptomatology, imaging findings, treatment regimens, peripheral blood profiles, EDSS scores, and MRI results. In addition, maternal drug concentrations, postpartum relapse rates, and neonatal development were monitored after delivery. Following the successful completion of the five-year follow-up, the research team plans to continue the prospective epidemiological study with ten-year follow-up phases. The aim of this study is to generate detailed clinical data on pregnancy-associated autoimmune diseases and to equip clinicians with evidence-based strategies for optimizing disease management during the reproductive age.",[28,64,65,66,67,68],"Multiple Sclerosis","Autoimmune Encephalitis","Myasthenia Gravis","Guillain-Barré Syndrome (GBS)","Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)",[70,64,71,72,67,68,73,74],"Neuromyelitis optica spectrum disorders (NMOSD)","Autoimmune encephalitis","myasthenia gravis","reproductive age","cohort study","RECRUITING","2026-06-13",{"date":78,"type":39},"2026-06-17",{"date":80,"type":39},"2024-04-21",{"date":82,"type":22},"2030-04",{"name":84,"class":46},"Third Affiliated Hospital, Sun Yat-Sen University",1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":85},"100625258","phase-3-modified-zipper-therapy-for-aqp4-igg-positive-neuromyelitis-optica-spectrum-disorder-100625258","NCT07420296","Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder","Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder: A Multicenter Randomized Controlled Trial Study","ELITE","Inclusion Criteria:\n\n1. Participants ≥ 18 years of age\n2. Definite diagnosis according to the 2015 IPND diagnostic criteria for AQP4-IgG-positive NMOSD\n3. Seropositivity for anti-AQP4 antibody.\n4. Time from onset to enrollment ≤ 30 days.\n5. For patients with optic neuritis: visual acuity ≤ 20\u002F200 at screening; for relapse cases, baseline visual acuity prior to this acute episode must have been ≥ 20\u002F60.\n6. For patients with longitudinal extensive transverse myelitis (LETM): EDSS score ≥ 5.5 at screening; for relapse cases, baseline EDSS score prior to this acute episode must have been ≤ 3.5.\n7. Ability to understand and voluntarily provide written informed consent-\n\nExclusion Criteria:\n\n1. Patients with concurrent neuromuscular disorders.\n2. Patients with severe coagulation dysfunction.\n3. Patients with known allergy to plasma or intravenous immunoglobulin (IVIG).\n4. Patients with active hepatitis B or C virus infection, human immunodeficiency virus (HIV) infection, or those deemed at high risk for the onset or reactivation of syphilis or tuberculosis at screening.\n5. Patients with active systemic infection at screening, or a history of severe chronic or recurrent infections.\n6. Pregnant or lactating patients.\n7. Patients with chronic, severe medical conditions that may affect study compliance.\n8. Patients with any clinically significant abnormal laboratory findings as determined by the investigator (e.g., severe anemia, leukopenia, thrombocytopenia, etc.).\n9. Patients whom the investigator considers unlikely to complete the study or unlikely to comply with the study requirements (for administrative reasons or otherwise).","80 Years",{"count":96,"type":22},198,[98],"PHASE3","Study Title: A National, Multicenter, Randomized Controlled Trial of the Modified Zipper Therapy in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (ELITE Study)\n\nBrief Summary:\n\nThe goal of this clinical trial is to evaluate the efficacy and safety of a novel sequential immunomodulation strategy, termed \"Modified Zipper Therapy,\" in patients with acute attacks of Aquaporin-4 antibody-positive Neuromyelitis Optica Spectrum Disorder (AQP4-IgG+ NMOSD). The therapy aims to enhance neurological recovery by combining plasma exchange (PE) with immediate complement inhibition using eculizumab, following high-dose corticosteroid pulse therapy.\n\nThe main questions this trial aims to answer are:\n\nEfficacy: Does the Modified Zipper Therapy (high-dose corticosteroids + plasma exchange + eculizumab) lead to a higher rate of neurological improvement at Week 12 compared to standard therapy (high-dose corticosteroids + plasma exchange alone)?\n\nFor patients with NMOSD-related optic neuritis (NMOSD-ON), improvement is defined as a gain of ≥10 letters on the ETDRS chart or a decrease of ≥0.2 LogMAR in best-corrected visual acuity (BCVA).\n\nFor patients with NMOSD-related longitudinally extensive transverse myelitis (NMOSD-LETM), improvement is defined as a reduction of ≥2 points on the Expanded Disability Status Scale (EDSS).\n\nSafety: What is the nature and frequency of adverse events experienced by participants receiving the Modified Zipper Therapy compared to those receiving standard therapy?\n\nResearchers will compare the Modified Zipper Therapy group to the Standard Therapy group to see if the novel combination is more effective in improving visual and functional outcomes in acute AQP4-IgG+ NMOSD.\n\nParticipants will:\n\nBe randomly assigned (like a coin toss) to receive either the Modified Zipper Therapy or the Standard Therapy.\n\nUndergo a treatment period involving intravenous corticosteroids and a series of plasma exchange sessions. The Modified Zipper Therapy group will also receive intravenous eculizumab infusions timed around the plasma exchange procedures.\n\nBe followed for 24 weeks after treatment completion.\n\nAttend scheduled clinic visits for comprehensive assessments including:\n\nVisual acuity testing (using ETDRS, Snellen, and low-contrast charts).\n\nNeurological function evaluations (EDSS and OSIS scores).\n\nOptical coherence tomography (OCT) and visual evoked potential (VEP) tests.\n\nMagnetic resonance imaging (MRI) scans of the optic nerves.\n\nSafety monitoring (physical exams, lab tests, ECGs).",[28],[34,102,103,104,105,106],"Eculizumab","Plasma exchange","Corticosteroid pulse therapy","Optic neuritis","Longitudinally extensive transverse myelitis","2026-05-11",{"date":109,"type":39},"2026-05-14",{"date":111,"type":39},"2026-01-01",{"date":113,"type":22},"2027-06-30",{"name":115,"class":46},"Tianjin Medical University General Hospital",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":126,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100619223","phase-1-a-study-of-c-car168-in-the-treatment-of-central-nervous-system-autoimmune-diseases-refractory-to-standard-therapy-100619223","NCT07341828","A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy","An Exploratory Clinical Study of Anti-CD20\u002FB-cell Maturation Antigen(BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy","Inclusion Criteria:\n\n* 18 to 70 years old at the time of signing the Informed Consent Form (ICF).\n* Diagnosed as Multiple Sclerosis (MS)\u002FNeuromyelitis Optica Spectrum Disorders (NMOSD)\u002FAutoimmune Encephalitis(AiE)\u002FStiff Person Spectrum Disorder(SPSD) according to recognized diagnostic criteria for at least 6 months.\n* Prior treatment failure with standard therapy.\n* Adequate bone marrow, coagulation, cardiopulmonary, liver and renal function.\n\nExclusion Criteria:\n\n* Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Treponema Pallidum (TP) positive, Cytomegalovirus (CMV) DNA positive, Epstein-Barr Virus (EBV) DNA positive.\n* Uncontrolled active infection.\n* Live vaccine injection within 4 weeks prior to signing the ICF.\n* Major organ transplantation history or bone marrow\u002Fhematopoietic stem cell transplantation history.\n* Severe cardiovascular diseases within the past 6 months prior to screening.\n* A history of ≥ Grade 2 bleeding within 4 weeks prior to screening, or requiring long-term anticoagulants treatment.\n* Inadequate washing time for previous treatment.\n* Previously treated with CAR-T cell products or genetically modified T cell therapies.\n* Pregnant or lactating women.\n* Severe central nervous system diseases or pathological changes.\n* Malignancy history within 5 years prior to signing the ICF.\n* Any contraindication to lumbar puncture.","70 Years",{"count":125,"type":22},15,[127],"PHASE1","This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases refractory to standard therapy",[130,28,65,131],"Multiple Sclerosis (MS)","Stiff Person Syndrome",[133],"CD20\u002FBCMA-directed CAR-T cells","2026-01-13",{"date":136,"type":39},"2026-01-15",{"date":138,"type":22},"2026-02",{"date":140,"type":22},"2029-02",{"name":142,"class":46},"Huashan Hospital",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":4},"100603121","phase-3-slow-vs-rapid-glucocorticoids-tapering-with-inebilizumab-in-nmosd-100603121","NCT07132398","Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD","The Efficacy of Slow - Tapering Versus Rapid - Tapering Glucocorticoid Strategies in Preventing Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD) When Combined With Inebilizumab: A Multicenter, Open - Label, Randomized Parallel - Controlled Clinical Trial","STARGlu-NMO","Inclusion Criteria:\n\n1. Ability and willingness to provide written informed consent and comply with the requirements of the study protocol.\n2. Age ≥18 years, regardless of sex.\n3. Diagnosis of NMOSD according to the 2015 International Panel for NMO Diagnosis (IPND) criteria.\n4. Serum AQP4-IgG antibody positivity at screening.\n5. An acute clinical attack (including the first attack) within 1 month before screening. After the acute attack was treated with high-dose corticosteroids, the current oral prednisone dose was reduced to 60 mg per day.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women, or women planning to become pregnant during the study period.\n2. Subjects with any serious acute, chronic, or recurrent infections (e.g., pneumonia, pyelonephritis, recurrent pneumonia, chronic bronchiectasis, tuberculosis, etc.).\n3. Carriers of hepatitis B virus, or patients with chronic active hepatitis B or C, other chronic liver diseases, or HIV infection.\n4. Abnormal liver function (ALT\u002FAST \\>2 times the upper limit of normal); moderate to severe renal impairment (glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m²).\n5. Active malignancy.\n6. Severe immunodeficiency.\n7. Receipt of any B-cell depleting therapy within 6 months prior to initiation of baseline treatment, with B-cell counts below the lower limit of normal.\n8. Receipt of other investigational treatments within 30 days prior to initiation of baseline treatment.",{"count":152,"type":22},170,[98],"Neuromyelitis optica spectrum disorder (NMOSD) is a central nervous system autoimmune condition mainly involving the spinal cord, optic nerves, and area postrema. The anti-aquaporin-4 (AQP4)-Immunoglobulin G (IgG) is a specific biomarker for NMOSD. Glucocorticoids(GCs) are used as first-line treatment for NMOSD. Oral glucocorticoids tapering is always suggested following the pused therapy in the maintenance phase. Inebilizumab, a humanized monoclonal antibody targeting CD19, has been proven effective in preventing NMOSD relapses. This study aims to evaluate and compare the efficacy and differences between glucocorticoids slow-tapering and rapid-tapering strategies combined with inebilizumab in preventing relapses in AQP4-IgG-seropositive NMOSD patients following an acute attack, with the goal of determining the optimal approach to steroid tapering and discontinuation after initiation of inebilizumab.",[156,28],"Neuromyelitis Optica (NMO)",[158,34,159,160],"NMO","Inebilizumab","Glucocorticoids","2025-08-12",{"date":163,"type":39},"2025-08-20",{"date":165,"type":22},"2025-09-01",{"date":167,"type":22},"2028-08-31",{"name":115,"class":46},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":123,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":185,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":85},"100535254","phase-1-a-study-of-c-car168-in-the-treatment-of-autoimmune-diseases-refractory-to-standard-therapy-100535254","NCT06249438","A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy","An Exploratory Clinical Study of Cluster of Differentiation Antigen 20(CD20)\u002FAnti-B-cell Maturation Antigen(BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy","CAR-AID","Inclusion Criteria:\n\n* 18 to 70 years old at the time of signing the Informed Consent Form (ICF).\n* Diagnosed as SLE\u002FImmune-Mediated Necrotizing Myopathy (IMNM)\u002FNeuromyelitis Optica Spectrum Disorders (NMOSD)\u002FMultiple Sclerosis (MS)\u002FMyasthenia Gravis (MG)\u002FSystemic Sclerosis (SSc) according to recognized diagnostic criteria for at least 6 months.\n* Remains disease active or relapses after treatment with standard of care therapy for at least 8 weeks with the dose stable for more than 2 weeks; patients should have been treated with at least two immunosuppressants (including immunosuppressants, biologics, and disease-modifying drug (DMD) ).\n* Adequate bone marrow, coagulation, cardiopulmonary, liver and renal function.\n\nExclusion Criteria:\n\n* Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Treponema Pallidum (TP) positive, Cytomegalovirus (CMV) DNA positive, Epstein-Barr Virus (EBV) DNA positive.\n* Uncontrolled active infection.\n* Live vaccine injection within 4 weeks prior to signing the ICF.\n* Major organ transplantation history or bone marrow\u002Fhematopoietic stem cell transplantation history.\n* Severe cardiovascular diseases within the past 6 months prior to screening.\n* ≥ Grade 2 bleeding within the past 30 days prior to screening, or requiring long-term anticoagulants treatment.\n* Inadequate washing time for previous treatment.\n* Previously treated with CAR-T cell products or genetically modified T cell therapies.\n* Pregnant or lactating women.\n* Severe central nervous system diseases or pathological changes.\n* Malignancy history within 5 years prior to signing the ICF.",{"count":178,"type":22},30,[127],"This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy",[182,183,28,130,66,184],"Systemic Lupus Erythematosus (SLE)","Immune-mediated Necrotizing Myopathy (IMNM)","Systemic Sclerosis (SSc)",[133],"2025-07-21",{"date":188,"type":39},"2025-07-25",{"date":190,"type":39},"2024-03-20",{"date":192,"type":22},"2040-03",{"name":194,"class":46},"RenJi Hospital",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":202,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":212,"locationsCount":85},"100579840","handle-a-real-world-study-on-satralizumab-in-nmosd-100579840","NCT06829524","HANDLE-a Real World Study on Satralizumab in NMOSD","A Real-World Practical Model of Integrated Management for Chinese Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) on Satralizumab","Inclusion Criteria:\n\n1. Patients have been diagnosed with NMOSD and tested seropositive for AQP4 antibody, ≥ 12 years old;\n2. EDSS score ≤ 8.5 at baseline;\n3. Patients have experienced ≥ 1 relapse of NMOSD in the last 12 months or ≥ 2 relapses in the last 24 months;\n4. Patients should have received or be anticipated to receive satralizumab treatment for at least 12 months;\n5. Patients understand the study procedures and sign the informed consent form indicating willingness to participate in the study (for those \\\u003C 18 years of age, the guardian should sign the informed consent form on behalf of the patient).\n\nExclusion Criteria:\n\n\\-","12 Years",{"count":60,"type":22},"This study is a single-center, retrospective-prospective, non-interventional cohort study to assess the clinical outcomes of Chinese NMOSD patients treated with satralizumab in a real-world patient management model by collecting follow-up data in clinical practice.",[28],"2025-03-14",{"date":208,"type":39},"2025-03-18",{"date":210,"type":22},"2025-03-31",{"date":113,"type":22},{"name":142,"class":46}]